Xuanbi Xiaoliu formula alleviates bone destruction by targeting the CREBBP/c-Myc axis with saponarin in multiple myeloma
Phytomedicine · 2026-11 · 162 · 158783
DOI: 10.1016/j.phymed.2026.158783 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine, 2026-11. Verfasst von Jinjun Qian und 15 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Provincial Hospital of Chinese Medicine, Nanjing, 210029, China; School of Med…. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Priority Academic Program Development of Jiangsu Higher Education Institutions, National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: Multiple myeloma (MM)-associated bone disease (MBD) is a devastating complication characterized by osteolytic lesions and poor survival. Xuanbi Xiaoliu Formula (XBXLF), an herbal formula for MM, has demonstrated promising therapeutic effects; however, its mechanism of action remains unclear. This study aimed to elucidate the pharmacological actions of XBXLF against MM, with a specific focus on its effects on MBD. METHODS: We employed an integrated approach combining a clinical trial, in vitro and in vivo models, serum pharmacochemistry, UPLC-MS/MS-based metabolomics, single-cell RNA sequencing, and molecular docking/CETSA assays. Functional experiments were performed using KMS28PE/CAG cell lines and RAW264.7 osteoclastogenesis models treated with XBXLF-containing serum or its identified components to investigate the underlying mechanisms. RESULTS: In MM patients with MBD, XBXLF add-on therapy significantly improved survival and quality of life, while reducing adverse events and bone pain markers. In murine models, XBXLF inhibited bone loss and osteoclastogenesis and promoted osteoblast activity. Mechanistically, serum containing XBXLF metabolites dose-dependently suppressed MM cell proliferation and osteoclast formation. RNA-seq analysis identified downregulation of CREBBP as a key event. Saponarin and 3-Hydroxycinnamic acid were identified as the major circulating bioactive components following XBXLF administration. Importantly, Saponarin directly bound to CREBBP and downregulated c-Myc, thereby inhibiting both MM cell proliferation and osteoclast differentiation. CONCLUSION: This study demonstrates that XBXLF improves clinical outcomes in MBD by modulating the CREBBP/c-Myc pathway through its active component Saponarin. These findings reveal a novel therapeutic strategy for MBD and provide a scientific basis for integrating XBXLF into combined treatment regimens for MM.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Provincial Hospital of Chinese Medicine, Nanjing, 210029, China; School of Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
- School of Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
- Xuyi Hospital of Traditional Chinese Medicine, Huaian, 223001, China.
- National and Local Collaborative Engineering Center of Chinese, Medicinal Resources Industrialization and Formulae Innovative Medicine, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
- Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Provincial Hospital of Chinese Medicine, Nanjing, 210029, China.
- Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Provincial Hospital of Chinese Medicine, Nanjing, 210029, China; The First Clinical College of Nanjing University of Chinese Medicine, Nanjing, 2100…
Förderung
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- National Natural Science Foundation of China
Zitieren
APA
Qian, J., Zhang, J., Deng, Z., Ge, X., Wang, C., Sun, S., Yu, X., Wu, H., Kong, X., Wei, J., Yang, W., Feng, X., Ye, S., Gu, C., Yang, Y., & Ni, H. (2026). Xuanbi Xiaoliu formula alleviates bone destruction by targeting the CREBBP/c-Myc axis with saponarin in multiple myeloma. Phytomedicine, 162, 158783. https://doi.org/10.1016/j.phymed.2026.158783
Vancouver
Qian J, Zhang J, Deng Z, Ge X, Wang C, Sun S, et al. Xuanbi Xiaoliu formula alleviates bone destruction by targeting the CREBBP/c-Myc axis with saponarin in multiple myeloma. Phytomedicine. 2026;162:158783. doi:10.1016/j.phymed.2026.158783
BibTeX
@article{Qian2026,
author = {Qian, Jinjun and Zhang, Jiale and Deng, Zhendong and Ge, Xiaoji and Wang, Cheng and Sun, Shanliang and Yu, Xichao and Wu, Hongjie and Kong, Xiangtu and Wei, JinRui and Yang, Wenhao and Feng, Xiaosu and Ye, Song and Gu, Chunyan and Yang, Ye and Ni, Haiwen},
title = {Xuanbi Xiaoliu formula alleviates bone destruction by targeting the CREBBP/c-Myc axis with saponarin in multiple myeloma},
journal = {Phytomedicine},
year = {2026},
volume = {162},
pages = {158783},
doi = {10.1016/j.phymed.2026.158783}
}
EUVIMED